Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGFBP-2 Vaccine + Chemo in Advanced Ovarian Cancer
NCT03029611Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Apr 2017
- Primary completion
- Oct 2018
- Modality
- Prophylactic Vaccines, RNA Aptamers, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pUMVC3-IGFBP-2 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by University of Washington. Started Apr 2017; status: terminated.
02
Drugs
pUMVC3-IGFBP-2
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03029611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029611.